Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.07M, +300.8% YoY · Filed Nov 5, 2026
Renovorx, Inc. (RNXT) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.1 million and a net loss of $3.6 million. Free cash flow was -$2.6 million. As of Sep 30, 2026 it held $10.4 million in cash and investments and $358,000 in total debt.
Revenue
$1.07M
+300.8% vs year-ago quarter
Net income
$-3.65M
-25.2% vs year-ago quarter
Operating cash flow
$-2.54M
-11.9% vs year-ago quarter
Free cash flow
$-2.56M
-12.7% vs year-ago quarter
EPS
$-0.08
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
48.25M
+31.7% vs year-ago quarter
Net cash
$10.05M
Q3 FY2026
Operating margin
-489.0%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- RNXT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1574094
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $909,000 | $563,000 | $238,000 | $266,000 |
| Operating income | -$3.2M | -$3.3M | -$3.5M | -$3.5M | -$3.2M |
| Net income | -$3.6M | -$2.9M | -$3.5M | -$2.9M | -$2.9M |
| Diluted EPS | -$0.08 | -$0.06 | -$0.09 | -$0.08 | -$0.08 |
| Operating cash flow | -$2.5M | -$2.9M | -$3.7M | -$3.0M | -$2.3M |
| Free cash flow | -$2.6M | -$2.9M | -$3.7M | -$3.0M | -$2.3M |
| Total assets | $12.4M | $11.5M | $14.0M | $8.1M | $11.2M |
| Total liabilities | $3.2M | $2.5M | $2.7M | $2.7M | $3.1M |
| Stockholders' equity | $9.3M | $9.0M | $11.3M | $5.4M | $8.1M |
| Cash and investments | $10.4M | $9.5M | $12.4M | $7.0M | $10.0M |
| Total debt | $358,000 | $390,000 | $186,000 | $212,000 | $236,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Results of operations
|
Aug 13, 2026 | Aug 12, 2026 |
| 8-K | Current report | Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Other events
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 2, 2026 | Jul 1, 2026 |
All 290 Renovorx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.